日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression

贝伐单抗在疾病进展后的治疗：卵巢癌、输卵管癌和腹膜癌患者在疾病进展后再次接受贝伐单抗治疗的影响

期刊:Gynecologic Oncology
影响因子:4.1
doi:10.1016/j.ygyno.2025.02.015
Asare, Amma; Previs, Rebecca Ann; Spinosa, Daniel; Fellman, Bryan; Scott, Amelia L; Mulder, Isabelle; Mahmoud, May; Enbaya, Ahmed; Siedel, Jean Hansen; Cobb, Lauren; Soliman, Pamela T; Sood, Anil K; Coleman, Robert L; Secord, Angeles Alvarez; Westin, Shannon N
肿瘤
肿瘤免疫
卵巢癌
发表日期：2025
文献求助 收藏

Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer

间隔性肿瘤减瘤手术时的病理分布情况可为高级别卵巢癌的个体化手术提供依据。

期刊:International Journal of Gynecological Cancer
影响因子:4.7
doi:10.1136/ijgc-2020-001597
Bailey, Courtney D; Previs, Rebecca; Fellman, Bryan M; Zaid, Tarrik; Huang, Marilyn; Brown, Alaina; Enbaya, Ahmed; Balakrishnan, Nyla; Broaddus, Russell R; Bodurka, Diane C; Soliman, Pamela; Fleming, Nicole D; Nick, Alpa; Sood, Anil K; Westin, Shannon Neville
肿瘤
肿瘤免疫
卵巢癌
发表日期：2021
文献求助 收藏